Journal article
Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the AMEND Trial Protocol
KO Sandström, OB Baltzersen, A Marsman, CK Lemvigh, VO Boer, KB Bojesen, M Nielsen, H Lundell, DK Sulaiman, ME Sørensen, B Fagerlund, AC Lahti, WT Syeda, C Pantelis, ET Petersen, BY Glenthøj, HR Siebner, BH Ebdrup
Frontiers in Psychiatry | Published : 2022
Abstract
Background: Antipsychotic drugs are primarily efficacious in treating positive symptoms by blocking the dopamine D2 receptor, but they fail to substantially improve negative symptoms and cognitive deficits. The limited efficacy may be attributed to the fact that the pathophysiology of psychosis involves multiple neurotransmitter systems. In patients with chronic schizophrenia, memantine, a non-competitive glutamatergic NMDA receptor antagonist, shows promise for ameliorating negative symptoms and improving cognition. Yet, it is unknown how memantine modulates glutamate levels, and memantine has not been investigated in patients with first-episode psychosis. Aims: This investigator-initiated ..
View full abstractGrants
Awarded by Lundbeckfonden
Funding Acknowledgements
This AMEND study was financed by Lundbeck Foundation Ascending Investigator grant, Journal nr. R344-2020-931; DKK 4,999,812/4 years (Granted to sponsor, BE). The sponsor has previously received grants from the Lundbeck Foundation.